GLP-1 drugs have also demonstrated potential in reducing risks of several substance use disorders such as those involving alcohol, tobacco, cannabis, opioids and stimulants. This may be due to the ...
The Centers for Medicare and Medicaid Services’ (CMS) announcement of 15 new drugs to be subject to price controls under the Inflation Reduction Act ( ...